- Home
- PTGX vs ICUI Comparison
PTGX vs ICUI Comparison
Compare PTGX & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- ICUI
- Stock Information
- Founded
- PTGX 2006
- ICUI 1984
- Country
- PTGX United States
- ICUI United States
- Employees
- PTGX N/A
- ICUI N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- ICUI Medical/Dental Instruments
- Sector
- PTGX Health Care
- ICUI Health Care
- Exchange
- PTGX Nasdaq
- ICUI Nasdaq
- Market Cap
- PTGX 3.3B
- ICUI 3.4B
- IPO Year
- PTGX 2016
- ICUI 1992
- Fundamental
- Price
- PTGX $53.00
- ICUI $133.44
- Analyst Decision
- PTGX Strong Buy
- ICUI Strong Buy
- Analyst Count
- PTGX 9
- ICUI 5
- Target Price
- PTGX $67.11
- ICUI $196.75
- AVG Volume (30 Days)
- PTGX 949.2K
- ICUI 222.9K
- Earning Date
- PTGX 08-05-2025
- ICUI 08-06-2025
- Dividend Yield
- PTGX N/A
- ICUI N/A
- EPS Growth
- PTGX N/A
- ICUI N/A
- EPS
- PTGX 0.86
- ICUI N/A
- Revenue
- PTGX $207,801,000.00
- ICUI $2,420,093,000.00
- Revenue This Year
- PTGX N/A
- ICUI N/A
- Revenue Next Year
- PTGX $53.09
- ICUI N/A
- P/E Ratio
- PTGX $61.45
- ICUI N/A
- Revenue Growth
- PTGX N/A
- ICUI 7.22
- 52 Week Low
- PTGX $32.50
- ICUI $117.92
- 52 Week High
- PTGX $60.60
- ICUI $196.26
- Technical
- Relative Strength Index (RSI)
- PTGX 53.99
- ICUI 50.47
- Support Level
- PTGX $49.38
- ICUI $129.26
- Resistance Level
- PTGX $51.51
- ICUI $139.41
- Average True Range (ATR)
- PTGX 2.02
- ICUI 4.24
- MACD
- PTGX -0.39
- ICUI 0.53
- Stochastic Oscillator
- PTGX 46.09
- ICUI 59.68
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.